ALEC RSI Chart
Last 7 days
-2.3%
Last 30 days
-6.1%
Last 90 days
-25.3%
Trailing 12 Months
-5.4%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 125.7M | 102.1M | 96.3M | 97.1M |
2022 | 227.4M | 300.7M | 133.2M | 133.6M |
2021 | 18.0M | 21.4M | 197.9M | 207.1M |
2020 | 22.8M | 19.0M | 22.2M | 21.1M |
2019 | 28.4M | 28.2M | 24.4M | 21.2M |
2018 | 8.4M | 15.2M | 21.6M | 27.7M |
2017 | 1.2M | 2.1M | 2.9M | 3.7M |
2016 | 0 | 0 | 0 | 416.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 19, 2024 | desouza errol b | acquired | - | - | 41,250 | - |
Mar 19, 2024 | altmeyer mark | acquired | - | - | 41,250 | - |
Mar 04, 2024 | grasso marc | sold | -39,561 | 6.9212 | -5,716 | chief financial officer |
Mar 04, 2024 | kenkare-mitra sara | sold | -70,386 | 6.9217 | -10,169 | president and head of r&d |
Mar 04, 2024 | rosenthal arnon | sold | -130,386 | 6.9218 | -18,837 | chief executive officer |
Mar 04, 2024 | romano gary | sold | -41,553 | 6.9245 | -6,001 | chief medical officer |
Dec 05, 2023 | garofalo elizabeth a. | gifted | - | - | -9,459 | - |
Dec 04, 2023 | romano gary | sold | -27,994 | 5.56 | -5,035 | chief medical officer |
Dec 04, 2023 | rosenthal arnon | sold | -132,500 | 5.56 | -23,831 | chief executive officer |
Dec 04, 2023 | grasso marc | sold | -25,431 | 5.56 | -4,574 | chief financial officer |
Which funds bought or sold ALEC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | reduced | -96.05 | -936 | 48.00 | -% |
Mar 21, 2024 | HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | unchanged | - | 60,750 | 323,190 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -20.55 | -770,888 | 35,004,600 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 130 | 2,954,390 | 4,562,850 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | 46,502 | 251,769 | -% |
Feb 27, 2024 | Beaird Harris Wealth Management, LLC | sold off | -100 | -1,018 | - | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 4.76 | 2,157,000 | 9,590,000 | -% |
Feb 15, 2024 | BARCLAYS PLC | added | 39.19 | 643,000 | 1,542,000 | -% |
Feb 15, 2024 | MEDICI CAPITAL LLC | added | 223 | 1,151,560 | 1,538,120 | 1.78% |
Feb 15, 2024 | JANE STREET GROUP, LLC | added | 69.87 | 439,124 | 841,292 | -% |
Unveiling Alector Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index
Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>
Returns of $10,000 invested in:
Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224
Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.
Peers (Alternatives to Alector Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Alector Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Revenue | 66.8% | 15.00 | 9.00 | 56.00 | 17.00 | 14.00 | 15.00 | 80.00 | 24.00 | 14.00 | 182 | 7.00 | 4.00 | 5.00 | 6.00 | 3.00 | 7.00 | 6.00 | 3.00 | 7.00 | 6.00 | 9.00 |
Operating Expenses | 4.9% | 63.00 | 60.00 | 60.00 | 67.00 | 70.00 | 63.00 | 70.00 | 69.00 | 70.00 | 56.00 | 62.00 | 57.00 | 58.00 | 60.00 | 50.00 | 49.00 | 38.00 | 37.00 | 34.00 | 26.00 | 28.00 |
S&GA Expenses | 11.6% | 15.00 | 13.00 | 14.00 | 15.00 | 15.00 | 14.00 | 16.00 | 16.00 | 17.00 | 13.00 | 14.00 | 11.00 | 13.00 | 16.00 | 16.00 | 15.00 | 13.00 | 8.00 | 8.00 | 6.00 | 4.00 |
R&D Expenses | 3.0% | 48.00 | 46.00 | 46.00 | 52.00 | 54.00 | 48.00 | 55.00 | 53.00 | 53.00 | 43.00 | 48.00 | 46.00 | 44.00 | 44.00 | 34.00 | 35.00 | 26.00 | 29.00 | 26.00 | 21.00 | 24.00 |
Income Taxes | 33.1% | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | 6.8% | -41.43 | -44.47 | 1.00 | -45.86 | -52.43 | -46.15 | 10.00 | -44.62 | -55.61 | 127 | -55.15 | -52.17 | -52.18 | -52.70 | -45.33 | -40.02 | -30.53 | -31.74 | -24.56 | -18.56 | -17.37 |
Net Income Margin | 8.5% | -1.34* | -1.47* | -1.40* | -1.07* | -1.00* | -1.02* | 0.12* | -0.13* | -0.18* | -0.17* | -9.90* | -11.22* | - | - | - | - | - | - | - | - | - |
Free Cashflow | 0.3% | -46.30 | -46.45 | -44.22 | -49.57 | -49.69 | -50.97 | -58.19 | 134 | -49.82 | 444 | -45.37 | -53.64 | - | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -7.5% | 622 | 672 | 709 | 748 | 788 | 837 | 890 | 954 | 815 | 854 | 397 | 440 | 488 | 532 | 572 | 619 | 422 | 450 | 477 | 496 | 308 |
Current Assets | -7.7% | 566 | 613 | 648 | 686 | 726 | 775 | 827 | 891 | 750 | 788 | 329 | 375 | 422 | 470 | 510 | 556 | 357 | 385 | 415 | 442 | 293 |
Cash Equivalents | -26.9% | 75.00 | 102 | 132 | 196 | 154 | 184 | 172 | 455 | 331 | 517 | 126 | 111 | 51.00 | 85.00 | 93.00 | 161 | 91.00 | 87.00 | 69.00 | 61.00 | 67.00 |
Net PPE | -5.4% | 22.00 | 23.00 | 24.00 | 25.00 | 26.00 | 26.00 | 26.00 | 26.00 | 27.00 | 28.00 | 29.00 | 29.00 | 30.00 | 31.00 | 32.00 | 33.00 | 34.00 | 34.00 | 32.00 | 22.00 | 11.00 |
Liabilities | -4.3% | 488 | 510 | 512 | 565 | 573 | 584 | 601 | 687 | 514 | 518 | 213 | 213 | 221 | 221 | 217 | 227 | 227 | 231 | 232 | 230 | 195 |
Current Liabilities | 14.5% | 178 | 155 | 132 | 99.00 | 94.00 | 161 | 149 | 143 | 140 | 133 | 74.00 | 64.00 | 68.00 | 71.00 | 66.00 | 72.00 | 62.00 | 59.00 | 67.00 | 56.00 | 48.00 |
Shareholder's Equity | -17.5% | 134 | 163 | 196 | 183 | 214 | 253 | 289 | 268 | 301 | 336 | 185 | 228 | 268 | 310 | 355 | 392 | 195 | 219 | 246 | 266 | - |
Retained Earnings | -6.2% | -710 | -668 | -624 | -625 | -579 | -527 | -481 | -490 | -446 | -390 | -517 | -462 | -410 | -357 | -305 | -259 | -219 | -189 | -157 | -132 | -114 |
Additional Paid-In Capital | 1.5% | 844 | 832 | 822 | 811 | 799 | 787 | 776 | 762 | 748 | 727 | 702 | 690 | 677 | 667 | 659 | 649 | 414 | 408 | 403 | 399 | 17.00 |
Shares Outstanding | 0.9% | 85.00 | 84.00 | 84.00 | 83.00 | 83.00 | 83.00 | 82.00 | 82.00 | 80.00 | 81.00 | 80.00 | 79.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | 384 | - | - | - | 627 | - | - | - | 1,193 | - | - | - | 1,376 | - | - | - | 549 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 1.0% | -46,070 | -46,540 | -43,004 | -48,548 | -48,925 | -49,053 | -57,442 | 135,091 | -49,265 | 445,052 | -44,543 | -52,693 | -47,658 | -40,821 | -45,942 | -32,313 | -28,827 | -28,863 | -18,052 | -23,566 | -17,654 |
Share Based Compensation | 14.7% | 11,542 | 10,059 | 10,222 | 10,975 | 10,963 | 10,766 | 12,478 | 11,939 | 12,706 | 10,201 | 9,078 | 8,800 | 8,902 | 8,030 | 6,948 | 6,642 | 5,238 | 4,104 | 3,694 | 3,245 | 2,660 |
Cashflow From Investing | 6.5% | 18,071 | 16,961 | -21,815 | 88,701 | 18,381 | 60,530 | -225,819 | -12,106 | -146,753 | -69,054 | 56,591 | 109,553 | 11,552 | 33,013 | -24,744 | -124,872 | 30,057 | 45,909 | 26,422 | -151,262 | 42,465 |
Cashflow From Financing | - | 590 | - | 881 | 1,079 | 636 | 489 | 906 | 2,483 | 8,638 | 14,821 | 2,962 | 3,874 | 1,096 | 286 | 2,270 | 228,461 | 1,437 | 720 | -116 | 170,312 | -1,280 |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | |
Total revenue | $ 97,062 | $ 133,617 | $ 207,085 |
Operating expenses: | |||
Research and development | 192,115 | 210,418 | 189,407 |
General and administrative | 56,687 | 61,033 | 55,038 |
Total operating expenses | 248,802 | 271,451 | 244,445 |
Loss from operations | (151,740) | (137,834) | (37,360) |
Other income, net | 26,561 | 7,778 | 1,031 |
Loss before income taxes | (125,179) | (130,056) | (36,329) |
Income tax expense | 5,212 | 3,254 | 0 |
Net loss | (130,391) | (133,310) | (36,329) |
Unrealized gain (loss) on marketable securities | 4,759 | (3,632) | (1,557) |
Comprehensive loss | $ (125,632) | $ (136,942) | $ (37,886) |
Net loss per share, basic | $ (1.56) | $ (1.62) | $ (0.45) |
Net loss per share, diluted | $ (1.56) | $ (1.62) | $ (0.45) |
Shares used in computing net loss per share, basic | 83,733,730 | 82,467,587 | 80,416,936 |
Shares used in computing net loss per share, diluted | 83,733,730 | 82,467,587 | 80,416,936 |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 74,555 | $ 154,323 |
Marketable securities | 474,306 | 558,528 |
Receivable from collaboration partner | 0 | 2,587 |
Prepaid expenses and other current assets | 16,946 | 10,997 |
Total current assets | 565,807 | 726,435 |
Property and equipment, net | 21,861 | 25,521 |
Operating lease right-of-use assets | 25,195 | 27,811 |
Restricted cash | 1,546 | 1,472 |
Other assets | 7,418 | 6,409 |
Total assets | 621,827 | 787,648 |
Current liabilities: | ||
Accounts payable | 3,775 | 4,189 |
Accrued clinical supply costs | 5,215 | 5,559 |
Accrued liabilities | 30,378 | 27,771 |
Deferred revenue, current portion | 82,975 | 48,231 |
Payable to collaboration partner | 7,703 | 0 |
Refund liability to collaboration partner, current portion | 39,440 | 0 |
Operating lease liabilities, current portion | 8,462 | 8,059 |
Total current liabilities | 177,948 | 93,809 |
Deferred revenue, long-term portion | 210,845 | 443,370 |
Refund liability to collaboration partner, long-term portion | 67,047 | 0 |
Operating lease liabilities, long-term portion | 30,456 | 35,268 |
Other long-term liabilities | 1,373 | 759 |
Total liabilities | 487,669 | 573,206 |
Commitments and contingencies (Note 4) | ||
Stockholders' equity: | ||
Common stock, $0.0001 par value; 200,000,000 shares authorized; 84,879,693 and 82,895,718 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively | 8 | 8 |
Additional paid-in capital | 844,044 | 798,696 |
Accumulated other comprehensive income (loss) | 184 | (4,575) |
Accumulated deficit | (710,078) | (579,687) |
Total stockholders' equity | 134,158 | 214,442 |
Total liabilities and stockholders' equity | $ 621,827 | $ 787,648 |